Thrombolytic Science, LLC (TSI) is a private, clinical stage biopharmaceutical company that was founded in 2006 based on the research of Harvard scientist Victor Gurewich into the potential use of prourokinase to break up blood clots.[1] Gurewich co-founded the company and the founding CEO is business person Alexis Wallace.[2]
 | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Headquarters | Cambridge, MA |
| Website | tsillc.net |
TSI's lead drug candidate is a synergistic sequential dual therapy combination of mutant prourokinase (the precursor form of urokinase) and a small dose of tPA [Tissue Plasminogen Activator]. TSI is developing its dual therapy as a potential treatment for conditions caused by blood clots, initially for ischemic stroke[2][3] and heart attacks.
The company completed a Phase I trial in The Netherlands in 2017.
The company raised $8 million by 2012 mostly from an undisclosed angel investor.[1][2]
References
edit- ^ a b Weintraub, Arlene (31 July 2012). "TSI Preps for Trials of New Clot-Busting Drug". Xconomy.
- ^ a b c Rhodes, Jennifer (6 February 2012). "Specifying Stroke" (PDF). BioCentury.
- ^ "TS 01". AdisInsight. Retrieved 22 February 2018.